1. Show article details.

    Greece crisis hits shares of some, but not all, U.S. multinationals

    Reuters – 3:22 PM ET 06/29/2015

    The collapse of Greek bailout talks hit shares of some U.S. companies with a high exposure to Europe on Monday, though the effect on others was more muted, as the euro reversed course midday to trade higher against the U.S. dollar.

  2. Show article details.

    Big business on winning side in U.S. top court's major rulings

    Reuters – 9:00 AM ET 06/27/2015

    Big business was on the winning side in the U.S. Supreme Court's two major cases of the year, with hundreds of employers pushing hard in favor of gay marriage and the healthcare industry backing the insurance subsidies available under Obamacare.

  3. Show article details.

    Even your favorite brands don't really know you

    MarketWatch – 6:17 PM ET 06/26/2015

    While the world's top consumer-goods companies and retailers say they want to serve the needs of their consumers, it turns out most are still struggling to get an accurate understanding of them. Only one in five executives in the consumer-goods and retail industry said they have "strong confidence" in their knowledge of consumers' behavior and another 20% say they couldn't "definitely claim" that they have an accurate picture of what items their own customers are buying from...

  4. Show article details.

    Many U.S. companies say supporting marriage equality makes business sense

    Reuters – 4:44 PM ET 06/26/2015

    From renaming an ice cream flavor to flying the gay movement's rainbow flag, many American corporations celebrated Friday's U.S. Supreme Court decision to legalize same-sex marriage and said it made good sense for their businesses.

  5. Show article details.

    The six best sectors for 2015's second half

    MarketWatch – 11:50 AM ET 06/25/2015

    The top performers place their sector bets for the rest of 2015. Manufacturing and finance are the two industries that will lead the market during the second half of 2015.. That at least is the collective judgment of the select few advisers I monitor who have the best records over both the long-term as well as the last year.

  6. Show article details.

    Boehringer says Pradaxa blood-thinning effect shown to be reversible

    Reuters – 9:36 AM ET 06/22/2015

    Germany's Boehringer said an experimental drug to reverse the blood-thinning effect of its stroke prevention pill Pradaxa was shown to be effective based on initial results of a late-stage study. Pradaxa was first to the mass market of stroke prevention in a new class of anti-clotting pills to replace decades-old warfarin, which requires dose adjustments and dietary restrictions.

  7. Show article details.

    30 stocks at risk from a government clampdown on buybacks

    MarketWatch – 8:52 AM ET 06/18/2015

    Two U.S. senators say share repurchases hurt the economy. Concerned that share buybacks are diverting too much money from investments that would otherwise boost the U.S. economy, lawmakers are angling to dial back stock repurchases. Given the elevated role buybacks have played in the bull market, this won't be good for equities.

  8. Show article details.

    Bert Vogelstein, M.D., Wins 2015 Dr. Paul Janssen Award for Biomedical Research

    PR Newswire – 7:45 AM ET 06/17/2015

    PHILADELPHIA, June 17, 2015 Johnson & Johnson today named Dr. Bert Vogelstein of Johns Hopkins University, Johns Hopkins Kimmel Cancer Center and the Howard Hughes Medical Institute, the winner of the 2015 Dr. Paul Janssen Award for Biomedical Research for his breakthroughs in oncology research, which have spanned more than two decades and have formed the basis of modern cancer research.

  9. Show article details.

    Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results

    PR Newswire – 4:07 PM ET 06/16/2015

    NEW BRUNSWICK, N.J., June 16, 2015 Johnson & Johnson (JNJ) will host a conference call for investors at 8:30 a.m. on Tuesday, July 14th, to review second-quarter results. Investors and other interested parties may access the conference call in the following ways: About Johnson & Johnson Caring for the world, one person at a time, inspires and unites the people of Johnson & Johnson.

  10. Show article details.

    Fitch Rates Cardinal Health's $1.5B Bond Issuance 'BBB+'; Outlook Stable

    Business Wire – 10:09 AM ET 06/16/2015

    Fitch Ratings has assigned a 'BBB+' rating to the $1.5 billion bond issuance by Cardinal Health, Inc. (CAH). Proceeds are expected to be used to help fund recently announced acquisitions, including the $1.9 billion acquisition of Cordis (JNJ) from Johnson & Johnson (JNJ) and the $1.1 billion purchase of the Harvard Drug Group . Cash on hand will fund the remainder of the acquisition costs.

  11. Show article details.

    India takes first step towards regulating medical devices

    Reuters – 3:47 AM ET 06/12/2015

    India plans to set up a regulator to oversee the country's $4 billion medical device industry, according to a draft policy released this month, the country's first effort to regulate an industry that covers everything from thermometers to prostheses.

  12. Show article details.

    Ghana halts Ebola vaccine trial due to community protests

    Reuters – 6:57 PM ET 06/10/2015

    Ghana has halted a plan to test two Ebola vaccines in an eastern town after legislators backed local protests against the trials sparked by fears of contamination, officials said on Wednesday.

  13. Show article details.

    Drug switch study bolsters case for copies of biotech medicine

    Reuters – 6:00 PM ET 06/09/2015

    New clinical data has bolstered the case for using cheaper copies of expensive biotech drugs by showing that patients with rheumatic diseases can be safely and effectively switched from original-brand medicine to a lower-cost version.

  14. Show article details.

    CEO and Director of Huntsman Cancer Institute Dr. Mary Beckerle Joins Johnson & Johnson Board of Directors

    PR Newswire – 4:30 PM ET 06/09/2015

    NEW BRUNSWICK, N.J., June 9, 2015 Johnson & Johnson (JNJ) announced today that its Board of Directors has appointed Mary Beckerle, Ph.D., Chief Executive Officer and Director of Huntsman Cancer Institute at the University of Utah, as a Director of Johnson & Johnson.

  15. Show article details.

    Genmab shares rise on cancer drug's FDA licence application

    Reuters – 8:47 AM ET 06/08/2015

    Shares in Genmab (GNMSF) rose almost 3 percent on Monday after partner Johnson and Johnson's (JNJ) announcement late on Friday that the companies have applied to U.S. authorities for a licence to market their blood cancer drug daratumumab.

  16. Show article details.

    Contact Lens Makers Ask Court to Block Utah Law Banning Price Fixing

    DJ Business News – 3:25 PM ET 06/03/2015

    SALT LAKE CITY-Three of the nation's largest contact lens manufacturers on Tuesday asked a federal appeals court in Denver to solidify an injunction blocking a Utah law banning price fixing. Johnson& Johnson, Novartis AG's Alcon and Bausch& Lomb, a unit of Valeant Pharmaceuticals International Inc. (VRX), said the measure was designed to help Utah-based discount retailer 1-800 Contacts Inc. and would violate interstate commerce rules. The Utah Attorney General said the companies...

  17. Show article details.

    Wall Street expects these health-care stocks to rise up to 55%

    MarketWatch – 2:20 PM ET 05/29/2015

    The sector's long-term track record of outperformance is likely to continue, analysts say. There's still value to be found in the stock market's best-performing sector, according to Wall Street analysts, despite the seemingly endless flow of articles saying equities are too expensive. It's easy to predict a "correction," which is typically defined as a broad stock market decline of 10% to 20%.

  18. Show article details.

    Scandal in World Soccer Pressures Sponsors

    DJ Business News – 10:15 PM ET 05/28/2015

    The corruption scandal engulfing FIFA is stoking long-festering concerns among corporate sponsors about soccer' s top governing body, but the marketing power of the world' s most popular game is so great that severing ties wouldn' t be easy. World soccer offers an unrivaled platform for brands to get their messages out in emerging markets that are vital sources of growth. Even as many FIFA sponsors have advertised their concerns since U.S. prosecutors this week...

  19. Show article details.

    Visa's tough stance on FIFA augurs more sponsor demands -experts

    Reuters – 8:12 PM ET 05/28/2015

    Visa Inc's (V) public warning to FIFA that it may end its sponsorship if world soccer's governing body does not quickly clean up its act will likely prompt other sponsors to take a tough stance as a major corruption scandal involving FIFA unfolds, brand experts said.

  20. Show article details.

    J&J Accepts Cardinal Health Offer for Heart Business

    DJ Business News – 8:55 AM ET 05/28/2015

    Johnson& Johnson said Thursday that it has formally accepted Cardinal Health Inc. (CAH) s March offer to buy its heart-product business for about $1.94 billion in cash. J&J said it accepted the offer after consulting with work councils and trade unions. The deal, subject to regulatory approvals, is expected to close near the end of the year.


Today's and Upcoming Events

  • Jul

    JNJ to announce Q2 earnings Before Market (Confirmed)

  • Jul

    JNJ Earnings Conference Call at 8:30 AM Listen

Past Events (last 90 days)

  • May

    JNJ ex-Dividend for $0.75 on 5/21/2015

    • Announce Date: 4/23/2015
    • Record Date: 5/26/2015
    • Pay Date: 6/9/2015
Data provided by Wall Street Horizon, Inc. © 2015

Technical Events

Technical Analysis

As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.

Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.